CVE:RX BioSyent (RX) Stock Price, News & Analysis C$17.15 0.00 (0.00%) As of 10/9/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendInsider TradesNews and Trends About BioSyent Stock (CVE:RX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioSyent alerts:Sign Up Key Stats Today's RangeC$16.70▼C$17.1550-Day RangeC$14.60▼C$17.4952-Week RangeC$10.65▼C$17.50Volume2,466 shsAverage Volume7,964 shsMarket CapitalizationC$192.63 millionP/E Ratio20.08Dividend Yield1.22%Price TargetN/AConsensus RatingStrong Buy Company Overview BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. Read More Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RX Stock News HeadlinesBioSyent Earns Spot on Canada’s Top Growing Companies 2026 ListSeptember 25, 2026 | tipranks.comBioSyent Named as One of Canada’s Top Growing Companies 2026 by The Globe and MailSeptember 25, 2026 | financialpost.comFI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 12 at 1:00 AM | Weiss Ratings (Ad)BioSyent Maintains Quarterly Dividend as Specialty Healthcare Growth ContinuesAugust 20, 2026 | tipranks.comBioSyent Declares Third Quarter 2026 DividendAugust 20, 2026 | financialpost.comFBioSyent Releases Financial Results for Q2 and H1 2026August 20, 2026 | financialpost.comFBioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026August 13, 2026 | financialpost.comFBioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)May 19, 2026 | financialpost.comFSee More Headlines RX Stock Analysis - Frequently Asked Questions How have RX shares performed this year? BioSyent's stock was trading at C$12.73 at the start of the year. Since then, RX stock has increased by 34.7% and is now trading at C$17.15. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) issued its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The business had revenue of $3.82 million for the quarter, compared to analyst estimates of $4.80 million. BioSyent had a net margin of 17.73% and a trailing twelve-month return on equity of 22.92%. How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F). Company Calendar Last Earnings5/25/2017Today10/12/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolCVE:RX CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)C$0.85 Trailing P/E Ratio20.08 Forward P/E Ratio24.70 P/E GrowthN/ANet IncomeC$7.02 million Net Margins17.73% Pretax MarginN/A Return on Equity22.92% Return on Assets12.86% Debt Debt-to-Equity Ratio6.85 Current Ratio2.07 Quick Ratio6.91 Sales & Book Value Annual SalesC$55.67 million Price / Sales3.46 Cash FlowC$5.58 per share Price / Cash Flow3.07 Book ValueC$4.02 per share Price / Book4.26Miscellaneous Outstanding Shares11,232,000Free FloatN/AMarket CapC$192.63 million OptionableNot Optionable Beta1.05 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (CVE:RX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...Paradigm Press | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
